SG11201407610WA - Cd33 antibodies and use of same to treat cancer - Google Patents

Cd33 antibodies and use of same to treat cancer

Info

Publication number
SG11201407610WA
SG11201407610WA SG11201407610WA SG11201407610WA SG11201407610WA SG 11201407610W A SG11201407610W A SG 11201407610WA SG 11201407610W A SG11201407610W A SG 11201407610WA SG 11201407610W A SG11201407610W A SG 11201407610WA SG 11201407610W A SG11201407610W A SG 11201407610WA
Authority
SG
Singapore
Prior art keywords
sgd
lllll
bothell
international
drive
Prior art date
Application number
SG11201407610WA
Inventor
May Kung Sutherland
Maureen Ryan
Django Sussman
Patrick Burke
Scott Jeffrey
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of SG11201407610WA publication Critical patent/SG11201407610WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 21 November 2013 (21.11.2013) WIPOIPCT (10) International Publication Number WO 2013/173496 A2 (51) International Patent Classification: C07K16/28 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/041209 15 May 2013 (15.05.2013) English English (30) Priority Data: 61/649,110 13/804,227 18 May 2012 (18.05.2012) US 14 March 2013 (14.03.2013) US (71) Applicant: SEATTLE GENETICS, INC. [US/US]; 21823 30th Drive Southeast, Bothell, Washington 98021 (US). (72) Inventors: SUTHERLAND, May Kung; 21823 30th Drive Southeast, Bothell, Washington 98021 (US). RYAN, Maureen; 21823 30th Drive Southeast, Bothell, Washing­ ton 98021 (US). SUSSMAN, Django; 21823 30th Drive Southeast, Bothell, Washington 98021 (US). BURKE, Patrick; 21823 30th Drive Southeast, Bothell, Washington 98021 (US). JEFFREY, Scott; 21823 30th Drive South­ east, Bothell, Washington 98021 (US). (74) Agents: LIEBESCHUETZ, Joe et al.; Alston & Bird LLP, 100 South Tyron Street, Bank of America Plaza, — Suite 4000, Charlotte, North Carolina 28280-4000 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: without international search report and to be republished upon receipt of that report (Rule 48.2(g)) [Continued on next page] (54) Title: CD33 ANTIBODIES AND USE OF SAME TO TREAT CANCER FIGURE 2 h2H12d h2H12d-SGD-1910 h0Qd-SGD-191O Mytotarg h2H12 h2H12-SGD-1269 hOO-SGD-1269 m2H12-SGD-1269 [ADC], ng/mi CJ o\ m i> • h2H12d • h2H12d-SGD-1910 O hOQd-SGD-tSIO • Mytotarg O h2H12 • h2H12-SGD-1269 x A hOO-SGD-1269 5 A i m2H12-SGD-1269 [ADCj, ng/mi i-H (57) Abstract: The invention provides murine, chimeric, and humanized antibodies that specifically bind to CD33. The antibodies © are useful for treatment and diagnoses of various cancers as well as detecting CD33. WO 2013/173496 A2 I lllll llllllll II llllll III lllll lllll lllll III III III lllll llll llll lllll lllll lllll lllllll llll llll — with sequence listing part of description (Rule 5.2(a))
SG11201407610WA 2012-05-18 2013-05-15 Cd33 antibodies and use of same to treat cancer SG11201407610WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261649110P 2012-05-18 2012-05-18
US13/804,227 US20130309223A1 (en) 2012-05-18 2013-03-14 CD33 Antibodies And Use Of Same To Treat Cancer
PCT/US2013/041209 WO2013173496A2 (en) 2012-05-18 2013-05-15 Cd33 antibodies and use of same to treat cancer

Publications (1)

Publication Number Publication Date
SG11201407610WA true SG11201407610WA (en) 2014-12-30

Family

ID=49581477

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407610WA SG11201407610WA (en) 2012-05-18 2013-05-15 Cd33 antibodies and use of same to treat cancer

Country Status (19)

Country Link
US (4) US20130309223A1 (en)
EP (2) EP3421048A1 (en)
JP (1) JP6454269B2 (en)
KR (2) KR102100467B1 (en)
CN (1) CN104936617B (en)
AU (3) AU2013262788B2 (en)
CA (1) CA2873286C (en)
DK (1) DK2850104T3 (en)
EA (1) EA029987B1 (en)
ES (1) ES2686618T3 (en)
HK (1) HK1206750A1 (en)
IL (1) IL235733B (en)
IN (1) IN2014DN10653A (en)
MX (1) MX350808B (en)
NZ (1) NZ702748A (en)
SG (1) SG11201407610WA (en)
TW (1) TWI593707B (en)
WO (1) WO2013173496A2 (en)
ZA (1) ZA201409224B (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2099823E (en) 2006-12-01 2014-12-22 Seattle Genetics Inc Variant target binding agents and uses thereof
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
NZ758049A (en) 2013-10-15 2024-03-22 Seagen Inc Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
CN105979963B (en) * 2013-11-25 2020-03-03 西雅图基因公司 Preparation of antibodies from CHO cell cultures for conjugation
TW201533060A (en) * 2013-12-13 2015-09-01 Genentech Inc Anti-CD33 antibodies and immunoconjugates
US10464997B2 (en) 2014-02-11 2019-11-05 Seattle Genetics, Inc. Selective reduction of proteins
EP3107557B1 (en) 2014-02-17 2021-06-09 Seagen Inc. Hydrophilic antibody-drug conjugates
WO2015150526A2 (en) 2014-04-03 2015-10-08 Cellectis Cd33 specific chimeric antigen receptors for cancer immunotherapy
TWI719942B (en) * 2014-07-21 2021-03-01 瑞士商諾華公司 Treatment of cancer using a cd33 chimeric antigen receptor
ES2842212T3 (en) 2015-01-26 2021-07-13 Cellectis Anti-CLL1 Specific Single Chain Chimeric Antigen Receptors (scCAR) for Cancer Immunotherapy
SG10201912085WA (en) 2015-06-12 2020-02-27 Alector Llc Anti-cd33 antibodies and methods of use thereof
EP3307779A2 (en) 2015-06-12 2018-04-18 Alector LLC Anti-cd33 antibodies and methods of use thereof
TW201709932A (en) 2015-06-12 2017-03-16 西雅圖遺傳學公司 CD123 antibodies and conjugates thereof
IL256295B2 (en) * 2015-06-30 2023-11-01 Seagen Inc Anti-ntb-a antibodies and related compositions and methods
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
AU2016363013B2 (en) 2015-12-04 2022-03-10 Seagen Inc. Conjugates of quaternized tubulysin compounds
WO2017160954A1 (en) 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
KR20180134351A (en) 2016-03-25 2018-12-18 시애틀 지네틱스, 인크. Process for the preparation of pegylated drug-linkers and intermediates thereof
WO2017180768A1 (en) * 2016-04-15 2017-10-19 Seattle Genetics, Inc. Combinations of cd33 antibody drug conjugates with hypomethylating agents
WO2017210621A1 (en) * 2016-06-03 2017-12-07 Seattle Genetics, Inc. Combination of cd33 antibody drug conjugates with chemotherapeutic agents
EP3469001A4 (en) 2016-06-09 2020-05-06 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with flt3 inhibitors
EA201990470A1 (en) 2016-08-09 2019-09-30 Сиэтл Дженетикс, Инк. MEDICINE CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSICAL AND CHEMICAL PROPERTIES
US11638762B2 (en) 2016-10-18 2023-05-02 Seagen Inc. Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors
MX2019006448A (en) 2016-12-01 2020-02-05 Regeneron Pharma Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging.
NZ756323A (en) 2017-02-28 2022-07-01 Seagen Inc Cysteine mutated antibodies for conjugation
JP2020512312A (en) 2017-03-24 2020-04-23 シアトル ジェネティックス， インコーポレイテッド Process for the preparation of glucuronide drug-linker and its intermediates
SG11201909563VA (en) 2017-04-27 2019-11-28 Seattle Genetics Inc Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
JP2020519640A (en) * 2017-05-17 2020-07-02 イミュノジェン， インコーポレイテッド Anti-CD33 immunoconjugate administration plan
US20200148767A1 (en) * 2017-05-26 2020-05-14 Fred Hutchinson Cancer Research Center Anti-cd33 antibodies and uses thereof
CR20190486A (en) * 2017-08-03 2020-02-10 Alector Llc Anti-cd33 antibodies and methods of use thereof
SI3601358T1 (en) 2017-08-03 2023-10-30 Alector Llc Anti-trem2 antibodies and methods of use thereof
CN111164208B (en) 2017-09-29 2023-08-04 第一三共株式会社 Antibody-pyrrolobenzodiazepine derivative conjugates
KR20200122351A (en) 2018-02-20 2020-10-27 시애틀 지네틱스, 인크. Hydrophobic auristatin F compound and conjugates thereof
EA202091976A1 (en) * 2018-02-20 2021-07-06 Драгонфлай Терапьютикс, Инк. VARIABLE ANTIBODY DOMAINS TARGETING CD33 AND THEIR APPLICATION
BR112021003670A2 (en) 2018-08-28 2021-05-18 Vor Biopharma, Inc. genetically modified hematopoietic stem cells and their uses
TW202016307A (en) * 2018-08-31 2020-05-01 美商阿列克特有限責任公司 Anti-cd33 antibodies and methods of use thereof
WO2020056170A1 (en) * 2018-09-12 2020-03-19 Fred Hutchinson Cancer Research Center Reducing cd33 expression to selectively protect therapeutic cells
JP2022501319A (en) * 2018-09-25 2022-01-06 アカデミア シニカAcademia Sinica Anti-Siglec antibody, pharmaceutical composition comprising it and its use
WO2020095107A1 (en) 2018-11-07 2020-05-14 Crispr Therapeutics Ag Anti-cd33 immune cell cancer therapy
EP3882349A4 (en) 2018-11-14 2023-04-05 Daiichi Sankyo Company, Limited (anti-cdh6 antibody)-(pyrrolobenzodiazepine derivative) conjugate
SG11202109860VA (en) 2019-03-25 2021-10-28 Daiichi Sankyo Co Ltd Anti-her2 antibody-pyrrolobenzodiazepine derivative conjugate
KR20210143237A (en) 2019-03-25 2021-11-26 다이이찌 산쿄 가부시키가이샤 Antibody-pyrrolobenzodiazepine derivative conjugate
EP3949988A4 (en) 2019-03-27 2022-11-16 Daiichi Sankyo Company, Limited Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor
EP4084821A4 (en) 2020-01-03 2024-04-24 Marengo Therapeutics Inc Multifunctional molecules that bind to cd33 and uses thereof
BR112022020332A2 (en) 2020-04-10 2022-12-13 Seagen Inc ANTIBODY-DRUG CONJUGATE COMPOUND, COMPOSITION, METHOD OF TREATMENT OF CANCER AND AN AUTOIMMUNE DISORDER
US20210402001A1 (en) * 2020-06-30 2021-12-30 David I. Cohen Zinc Porters, and their Monoclonal Antibody Conjugates, for the Prevention and Treatment of COVID-19 (SARS-CoV-2), Other Infections, and Cancers
EP4209506A1 (en) 2020-09-02 2023-07-12 Daiichi Sankyo Company, Limited Novel endo-?-n-acetylglucosaminidase
KR20230107628A (en) * 2020-11-11 2023-07-17 버사퓨틱스 인코포레이티드 Antibody variants against the WNT receptor RYK
EP4277664A1 (en) 2021-01-13 2023-11-22 Memorial Sloan Kettering Cancer Center Antibody-pyrrolobenzodiazepine derivative conjugate
US20240115607A1 (en) 2021-01-26 2024-04-11 Cytocares (Shanghai) Inc. Chimeric antigen receptor (car) constructs and nk cells expressing car constructs
AU2022262600A1 (en) 2021-04-20 2023-10-05 Seagen Inc. Modulation of antibody-dependent cellular cytotoxicity
KR20240015670A (en) 2021-05-28 2024-02-05 씨젠 인크. Anthracycline antibody conjugate
TW202400137A (en) 2022-03-17 2024-01-01 美商思進公司 Camptothecin conjugates
CN116375874B (en) * 2023-04-14 2023-12-26 上海精翰生物科技有限公司 CD33 antibody and application thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (en) 1982-01-22 1985-10-31 Sandoz Ag METHOD FOR IN VITRO PRODUCTION OF HYBRID OMEN WHAT human monoclonal antibodies GENERATE.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69133566T2 (en) 1990-01-12 2007-12-06 Amgen Fremont Inc. Formation of xenogenic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0814159T3 (en) 1990-08-29 2005-10-24 Genpharm Int Transgenic, non-human animals capable of forming heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
DE122004000008I1 (en) 1991-06-14 2005-06-09 Genentech Inc Humanized heregulin antibody.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
JPH07503132A (en) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド Transgenic non-human animals capable of producing xenoantibodies
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5914349A (en) 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
DE60036082T2 (en) 1999-02-05 2008-06-12 Samsung Electronics Co., Ltd., Suwon METHOD AND DEVICE FOR RECONSTRUCTING TEXTURE IMAGES
CN1468259A (en) * 2000-08-08 2004-01-14 ͨ��ҽ�ƹ�˾ Immunotherapy for chronic myelocytic leukemia
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
ES2544527T3 (en) 2002-07-31 2015-09-01 Seattle Genetics, Inc. Drug conjugates and their use to treat cancer, an autoimmune disease or an infectious disease
CA2504818C (en) * 2002-11-07 2013-04-23 Immunogen, Inc. Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same
WO2004078215A2 (en) 2003-02-28 2004-09-16 The Board Of Trustees Of The University Of Illinois Use of antibody conjugated deoxycytidine kinase for adept
SG149815A1 (en) 2003-11-06 2009-02-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
TW200539855A (en) 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
US7927594B2 (en) 2004-07-30 2011-04-19 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide
CN101065151B (en) 2004-09-23 2014-12-10 健泰科生物技术公司 Cysteine engineered antibodies and conjugates
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
CA2614436C (en) 2005-07-07 2016-05-17 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
US7910702B2 (en) 2006-07-28 2011-03-22 The Governors Of The University Of Alberta Recombinant antibodies to sclerotinia antigens
PT2099823E (en) 2006-12-01 2014-12-22 Seattle Genetics Inc Variant target binding agents and uses thereof
CA2702555A1 (en) 2007-10-19 2009-04-23 Seattle Genetics, Inc. Cd19 binding agents and uses thereof
CA2733223C (en) 2008-08-05 2018-02-27 Toray Industries, Inc. Pharmaceutical composition comprising anti-caprin-1 antibody for treatment and prevention of cancers
GB0819095D0 (en) * 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
EP2406285B1 (en) * 2009-03-10 2016-03-09 Gene Techno Science Co., Ltd. Generation, expression and characterization of the humanized k33n monoclonal antibody
DE102009045006A1 (en) 2009-09-25 2011-04-14 Technische Universität Dresden Anti-CD33 antibodies and their use for immuno-targeting in the treatment of CD33-associated diseases
CN103068405A (en) 2010-04-15 2013-04-24 西雅图基因公司 Targeted pyrrolobenzodiazapine conjugates
UA112062C2 (en) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх CD33-Binding Agent
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
PT2900277T (en) * 2012-12-13 2022-05-25 Immunomedics Inc Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
EP2970444A4 (en) * 2013-03-13 2016-11-09 Seattle Genetics Inc Cyclodextrin and antibody-drug conjugate formulations

Also Published As

Publication number Publication date
AU2018203508C1 (en) 2020-09-10
TW201408700A (en) 2014-03-01
AU2013262788A1 (en) 2015-01-22
EP2850104B1 (en) 2018-07-11
AU2020203365A1 (en) 2020-06-11
JP6454269B2 (en) 2019-01-16
MX350808B (en) 2017-09-20
ES2686618T3 (en) 2018-10-18
EP2850104A2 (en) 2015-03-25
IL235733B (en) 2021-07-29
US20150147316A1 (en) 2015-05-28
MX2014013866A (en) 2015-05-07
US20210047404A1 (en) 2021-02-18
EP2850104A4 (en) 2016-07-13
KR102241478B1 (en) 2021-04-16
HK1206750A1 (en) 2016-01-15
WO2013173496A3 (en) 2015-06-04
CA2873286A1 (en) 2013-11-21
WO2013173496A2 (en) 2013-11-21
US10787514B2 (en) 2020-09-29
AU2018203508A1 (en) 2018-06-07
EA201492137A1 (en) 2015-08-31
DK2850104T3 (en) 2018-09-10
KR20150013321A (en) 2015-02-04
AU2013262788B2 (en) 2018-02-22
AU2018203508B2 (en) 2020-03-12
KR102100467B1 (en) 2020-04-14
IN2014DN10653A (en) 2015-09-11
KR20200039031A (en) 2020-04-14
EP3421048A1 (en) 2019-01-02
NZ702748A (en) 2017-04-28
CA2873286C (en) 2023-08-01
TWI593707B (en) 2017-08-01
BR112014028507A2 (en) 2017-06-27
CN104936617A (en) 2015-09-23
US20170204180A1 (en) 2017-07-20
CN104936617B (en) 2018-11-02
JP2015520758A (en) 2015-07-23
AU2020203365B2 (en) 2023-04-20
ZA201409224B (en) 2016-08-31
IL235733A0 (en) 2015-01-29
US9587019B2 (en) 2017-03-07
EA029987B1 (en) 2018-06-29
US20130309223A1 (en) 2013-11-21

Similar Documents

Publication Publication Date Title
SG11201407610WA (en) Cd33 antibodies and use of same to treat cancer
SG11201806261XA (en) Bcma antibodies and use of same to treat cancer and immunological disorders
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201807437XA (en) Antibodies specific to human poliovirus receptor (pvr)
SG11201909081YA (en) Anti-ilt4 antibodies and antigen-binding fragments
SG11201804161VA (en) Compositions comprising bacterial strains
SG11201408002TA (en) Multi-parameter diabetes risk evaluations
SG11201407888RA (en) Method of sequence determination using sequence tags
SG11201804086VA (en) Methods and compositions for nucleic acid analysis
SG11201407233RA (en) Ethylene oligomerization process
SG11201408780XA (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
SG11201407534PA (en) New diazaspirocycloalkane and azaspirocycloalkane
SG11201407669QA (en) Methods for improving safety of blood-brain barrier transport
SG11201408385TA (en) Methods of detecting diseases or conditions
SG11201408022XA (en) Enterprise triggered 2chk association
SG11201407898WA (en) Electrode testing apparatus
SG11201407859YA (en) Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201407200TA (en) Liquid formulation
SG11201407370QA (en) Humanized il-7 rodents
SG11201903785TA (en) Bivalent antibodies masked by coiled coils
SG11201403106SA (en) Anti-phf-tau antibodies and their uses
SG11201407891QA (en) Interest profile of a user of a mobile application
SG11201809830WA (en) Selective reduction of cysteine-engineered antibodies